StockData
Veru Inc. logo

Veru Inc. (VERU) company profile

VERUNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 10, 2026Score 6/30
$2.14+0.06 (+2.88%)

Close on Nov 17, 2026Market cap $36.49MP/E –Yield –

About Veru

Pharmaceutical Preparations, SIC 2834

Veru Inc. is a clinical-stage biopharmaceutical company that develops treatments for cardiometabolic and inflammatory diseases. The firm focuses on two drug candidates: enobosarm and sabizabulin. Enobosarm is an oral selective androgen receptor modulator designed to preserve lean muscle tissue and increase fat reduction in individuals undergoing weight-loss therapy with GLP-1 receptor agonists. Sabizabulin is an oral microtubule disruptor intended to diminish vascular inflammation in patients with atherosclerotic cardiovascular conditions. Through these investigational programs, the company targets overweight individuals, older adults with obesity at risk of muscle loss, and patients diagnosed with coronary artery disease.

The company operates as a Wisconsin corporation. Following the divestment of its commercial internal condom business, which previously included operating entities in the United Kingdom and Malaysia, its current activities focus on clinical research programs within the United States. Its clinical scale includes multicenter studies involving several hundred trial participants across its metabolic and cardiovascular programs.

Summary of the business section of Veru's latest annual report, written by StockData.

Company profile

Company

Legal name
Veru Inc.
Founded
1971
Headquarters
Miami, FL
Address
2916 N. Miami Avenue, Suite 1000 33127
Phone
(312) 595-9123
Employees
20, Sep 30, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Wisconsin
Fiscal year ends
September 30
Auditor
Cherry Bekaert LLP, Atlanta, Georgia

Stock & identifiers

Ticker
VERU
Exchange
Nasdaq
IPO date
Feb 11, 1999
Shares outstanding
17M, Aug 6, 2026
Public float
$64.10M, Mar 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Aug 11, 2025
SEC CIK
863894
CUSIP
92536C202
ISIN
US92536C2026
FIGI
BBG000G12J78
Share class FIGI
BBG001SCF2T8
LEI
529900ER63TFLEIJV631
EIN
39-1144397

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Harry FischChief Corporate Officer, Director8,013,832
Mitchell Shuster SteinerPresident and CEO, Director7,086,709
K. Gary BarnetteChief Scientific Officer2,300
Michele GrecoChief Admin Officer and CFO96,178
Michael L. RankowitzDirector250,000
Lucy LuDirector9,800
Grace HyunDirector14,790
Loren Mark KatzovitzDirector224,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.65M$1.38M$855.21K$3–
FY2024$1.98M$1.83M$925.69K$7–
FY2023$4.71M-$5.95M$1.62M$6–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Mitchell S. Steiner
Chairman, President and Chief Executive Officer
$836.21K$163.30K$636.16K$14.00K$1.65M-17%
K. Gary Barnette
Chief Scientific Officer
$615.62K$44.93K$266.46K$14.00K$941.01K-6%
Harry Fisch
Vice Chairman and Chief Corporate Officer
$505.63K$44.93K$218.86K–$769.42K-9%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 1, 2025, the Company had 20 full-time employees, all of whom are located in the U.S.”

Corporate history

Events identified from SEC filings

DateEventDetails
Feb 28, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 3, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 30, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 22, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 28, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 15, 2024Late filingNotification of late filing
Jan 26, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 20, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 2, 2018Late filingNotification of late filing
Aug 1, 2017Name changeName changed from FEMALE HEALTH CO to Veru Inc.
Nov 2, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 8, 2016Merger voteDefinitive merger proxy statement
Jan 4, 2016BankruptcyBankruptcy or receivership (8-K Item 1.03)
Mar 31, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 23, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 19, 2013Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 8, 2009DelistingNotice of delisting from exchange (Form 25)
Jun 8, 2009ListingRegistration of securities on an exchange (Form 8-A)
May 29, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 6, 2007ListingRegistration of securities on an exchange (Form 8-A)
Mar 30, 2007Tender offerThird-party tender offer for the company's shares

See a number that looks wrong?